 "Covid nasal vaccine")
Covaxin maker Bharat Biotech is targeting to make one billion doses annually of its intranasal vaccine in 2022 that is under clinical trials now.
The Hyderabad-based vaccine maker is also looking for global partners to manufacture and distribute the vaccine overseas.
BBV154, the intranasal vaccine, can be administered as a nasal spray or a drop. It cannot be taken at home though, but needs to be administered in a clinical setting.
The adenovirus vector-based vaccine helps trigger generation of IgA antibodies that line the nasal mucosa.
Bharat Biotech claims that the vaccine helps reduce transmission of the Sars-CoV-2 virus as it attacks the virus
